ViiV Healthcare Archives

gene therapy blood disorder hemophilia b

News and Trends 4 Feb 2021

HIV Drug Approvals Lift Hopes Amid Missed UN Targets

The recent approvals of long-acting HIV injections promise to lighten the load of HIV sufferers around the world. However, a vital UN deadline for improving global HIV healthcare has slipped away. At the end of January, ViiV Healthcare’s Cabenuva became the first long-acting HIV treatment to be approved by the FDA. This decision, in addition […]

February 4, 2021 - 6 minutesmins - By Anita Chakraverty

News and Trends 23 Mar 2020

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […]

March 23, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […]

November 22, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Aug 2019

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jul 2019

HIV Drug Suppresses Virus for Almost Two Years When Other Treatments Fail

A first-in-class HIV treatment developed by the UK company ViiV Healthcare has suppressed the virus in people who have become resistant to other antiretroviral drugs, providing protection for at least 96 weeks. The phase III trial tested ViiV Healthcare’s first-in-class drug fostemsavir in 272 HIV-infected people who had failed to respond to approved antiretroviral drugs. […]

July 23, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jul 2019

EU Approves Two-Drug Pill as First-Line Treatment for HIV

The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […]

July 3, 2019 - 2 minutesmins - By Jonathan Smith

GSK ViiV Healthcare Double HIV Treatment

News and Trends 4 Apr 2019

Update: Two-Drug HIV Treatment Effective for up to Three Years

Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […]

April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2018

Forget Daily Pills: HIV Could Be Treated With Monthly Injections

A monthly antiviral injection may be as good as daily HIV drugs for suppressing infections, reports the British biotech ViiV Healthcare. This could make the treatment of HIV easier for patients and improve compliance. In the first five months of a Phase IIb trial, the company gave 274 HIV-infected adults three daily oral antiretrovirals. After […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Jul 2018

Two Drugs as Good as Three for Treating HIV

ViiV Healthcare reports promising data from two HIV treatments with two drugs instead of the usual three, which have the potential to reduce the side effects of antiretroviral therapy in the long term. People infected with HIV are treated with lifelong antiretroviral therapy, which traditionally consists of three or more different drugs. The British […]

July 25, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Feb 2018

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 13 Sep 2017

The 10 Most Innovative HIV Treatments to Defeat AIDS

This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people living with HIV worldwide, the search for an effective treatment that can overcome the fast evolution of the virus is rapidly gaining traction. In Europe, […]

September 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

ViiV Healthcare

HIV Drug Approvals Lift Hopes Amid Missed UN Targets

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

HIV Drug Suppresses Virus for Almost Two Years When Other Treatments Fail

EU Approves Two-Drug Pill as First-Line Treatment for HIV

Update: Two-Drug HIV Treatment Effective for up to Three Years

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Forget Daily Pills: HIV Could Be Treated With Monthly Injections

Two Drugs as Good as Three for Treating HIV

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

The 10 Most Innovative HIV Treatments to Defeat AIDS

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!